DDR2 and lung cancer: Having determined the key receptor-phosphorylation sites and signalling pathways activated by DDR2, we further demonstrated that the mechanism of action for kinase-domain mutations of DDR2 in lung cancer was kinase inactivation and the inability to initiate receptor phosphorylation and downstream signalling.